AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18203894 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g MC
Number of subjects: 50
Study 18203894 — intervention group
Group type: COMPARATOR
Intervention: Control (2 g cellulose)
Number of subjects: 50
Study 15831351 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass surgery
Number of subjects: 8
Study 15831351 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal BP rhythm)
Number of subjects: 8
Study 12143264 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (Plavix)
Number of subjects: 0
Study 12143264 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study 10521098 — intervention group
Group type: EXPERIMENTAL
Intervention: Single IUI 34 hours after hCG administration (Group A)
Number of subjects: 273
Study 10521098 — intervention group
Group type: EXPERIMENTAL
Intervention: Double IUI 12 hours and 34 hours after hCG administration (Group B)
Number of subjects: 273
Study 10521098 — intervention group
Group type: EXPERIMENTAL
Intervention: Double IUI 34 hours and 60 hours after hCG administration (Group C)
Number of subjects: 273
Study 8622099 — intervention group
Group type: EXPERIMENTAL
Intervention: Isepamicin once daily plus ceftriaxone
Number of subjects: 235
Study 8622099 — intervention group
Group type: COMPARATOR
Intervention: Amikacin twice daily plus ceftriaxone
Number of subjects: 235
Study 1828561 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (3 mg daily for 16 weeks)
Number of subjects: 20
Study 1828561 — intervention group
Group type: COMPARATOR
Intervention: Lactose (placebo, 3 mg daily for 16 weeks)
Number of subjects: 20
Study 1828561 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Folic acid and Lactose)
Number of subjects: 20
Study 6966835 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacids
Number of subjects: 77
Study 6966835 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 77
Study 6966835 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 77
Study 31699517 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (0.4 mEq per kg of ideal body weight per day) (n=74)
Number of subjects: 149
Study 31699517 — intervention group
Group type: COMPARATOR
Intervention: Identical‐appearing placebo (n=75)
Number of subjects: 149
Study 29306619 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mL of glucose 10% (50 g glucose)
Number of subjects: 63
Study 29306619 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mL of 2% lipid emulsion (soybean 30%, medium chain triglycerides (TG) 30%, olive oil 25%, fish oil 15%, and 20 mg vitamin E)
Number of subjects: 63
Study 29306619 — intervention group
Group type: COMPARATOR
Intervention: Conventional preoperative fasting (C group)
Number of subjects: 63
Study 27628940 — intervention group
Group type: EXPERIMENTAL
Intervention: PEERS® for Young Adults intervention
Number of subjects: 56
Study 25676122 — intervention group
Group type: EXPERIMENTAL
Intervention: s-ketamine
Number of subjects: 0
Study 25676122 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 23937849 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine and Perindopril
Number of subjects: 120
Study 23937849 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide sustained release tablets and Perindopril
Number of subjects: 120
Study 23937849 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study 20065611 — intervention group
Group type: COMPARATOR
Intervention: Never-smokers
Number of subjects: 724
Study 20065611 — intervention group
Group type: COMPARATOR
Intervention: Ex-smokers
Number of subjects: 724
Study 20065611 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 724
Study 20065611 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy-smokers (≥30 pack x year)
Number of subjects: 724
Study 20065611 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-smokers (<30 pack x year)
Number of subjects: 724
Study 19058658 — intervention group
Group type: EXPERIMENTAL
Intervention: Displays of moral credentials
Number of subjects: 0
Study 17083353 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum BB536
Number of subjects: 44
Study 17083353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 15325873 — intervention group
Group type: EXPERIMENTAL
Intervention: Ground coverings/barriers plus raised garden bed (RB)
Number of subjects: 0
Study 15325873 — intervention group
Group type: EXPERIMENTAL
Intervention: Ground coverings/barriers only (no raised bed, NRB)
Number of subjects: 0
Study 15325873 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 11104589 — intervention group
Group type: EXPERIMENTAL
Intervention: Alanyl-glutamine supplementation (0.5 g/kg BW/day)
Number of subjects: 37
Study 11104589 — intervention group
Group type: COMPARATOR
Intervention: Standard isonitrogenous, isoenergetic TPN
Number of subjects: 37
Study 9046717 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 100 mg intramuscularly
Number of subjects: 64
Study 9046717 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 500 mg intramuscularly
Number of subjects: 64
Study 9046717 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 64
Study 8314685 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 20-40 mg/day given at bedtime
Number of subjects: 77
Study 8314685 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 77
Study 8314685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 3089202 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam
Number of subjects: 20
Study 31352467 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure therapy (n=25; female/male=24/1)
Number of subjects: 45
Study 31352467 — intervention group
Group type: COMPARATOR
Intervention: Progressive muscle relaxation (PMR; n=20; female/male=17/3)
Number of subjects: 45
Study 31352467 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure therapy
Number of subjects: 45
Study 30022470 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid autoimmune disease patients
Number of subjects: 357
Study 30022470 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 357
Study 26413774 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting for one hour per day for five consecutive days
Number of subjects: 36
Study 26413774 — intervention group
Group type: COMPARATOR
Intervention: Standing for one hour per day for five consecutive days
Number of subjects: 36
Study 24872002 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobutrol (0.1 mmol/kg)
Number of subjects: 20
Study 24872002 — intervention group
Group type: COMPARATOR
Intervention: Gadobenate dimeglumine (0.1 mmol/kg)
Number of subjects: 20
Study 23098346 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 12.5 mg
Number of subjects: 9948
Study 23098346 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 25 mg
Number of subjects: 9948
Study 23098346 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 9948
Study 23098346 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 100 mg
Number of subjects: 9948
Study 23098346 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg / Hydrochlorothiazide 12.5 mg
Number of subjects: 9948
Study 23098346 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 100 mg / Hydrochlorothiazide 25 mg
Number of subjects: 9948
Study 23098346 — intervention group
Group type: COMPARATOR
Intervention: Control group (Losartan 100 mg/Hydrochlorothiazide 25 mg)
Number of subjects: 9948
Study 20631555 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐mg aripiprazole for 2 weeks
Number of subjects: 0
Study 20631555 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 0
Study 18346606 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 250 mg and placebo
Number of subjects: 80
Study 18346606 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 250 mg and ranitidine 150 mg
Number of subjects: 80
Study 18346606 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg and metoclopramide 10 mg
Number of subjects: 80
Study 18346606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 15934081 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous treatment with NSAIDs
Number of subjects: 215
Study 15934081 — intervention group
Group type: COMPARATOR
Intervention: On-demand treatment with NSAIDs
Number of subjects: 215
Study 12870201 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutrimazole 1% powder applied twice daily for 4 weeks
Number of subjects: 222
Study 12870201 — intervention group
Group type: COMPARATOR
Intervention: Bifonazole 1% powder applied twice daily for 4 weeks
Number of subjects: 222
Study 10895107 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (two oral supplements each day during hospital stay)
Number of subjects: 84
Study 10895107 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nutritional supplementation)
Number of subjects: 84
Study 8792511 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone
Number of subjects: 2
Study 8792511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 8792511 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 2
Study 8792511 — intervention group
Group type: COMPARATOR
Intervention: Hydroxychloroquine
Number of subjects: 2
Study 1541318 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinacidil (25 to 100 mg daily for 8 weeks)
Number of subjects: 52
Study 1541318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 2988337 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate-leucovorin rescue plus Cytoxan
Number of subjects: 0
Study 2988337 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil plus Cytoxan
Number of subjects: 0
Study 2988337 — intervention group
Group type: COMPARATOR
Intervention: Melphalan or actinomycin D-5-fluorouracil-Cytoxan
Number of subjects: 0
Study 2988337 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil-Cytoxan
Number of subjects: 0
Study 29504471 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal hemorrhoidal dearterialization (THD)
Number of subjects: 100
Study 29504471 — intervention group
Group type: COMPARATOR
Intervention: Stapled hemorrhoidopexy (SH)
Number of subjects: 100
Study 27377404 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice Facilitation (PF) for one year including onsite visits and shared learning
Number of subjects: 250
Study 27377404 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 250
Study 22878539 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection into neck area
Number of subjects: 0
Study 22878539 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection into thigh muscle
Number of subjects: 0
Study 22878539 — intervention group
Group type: COMPARATOR
Intervention: Intravenous injection
Number of subjects: 0
Study 21098510 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (ascorbic acid) preoperatively and postoperatively (Group A, n=85)
Number of subjects: 170
Study 21098510 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin C, Group B, n=85)
Number of subjects: 170
Study 21098510 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C group (Group A)
Number of subjects: 170
Study 19318448 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA 50 mg
Number of subjects: 40
Study 19318448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 17261985 — intervention group
Group type: COMPARATOR
Intervention: Vibration only (Group 3)
Number of subjects: 45
Study 17261985 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration exercise (Group 1)
Number of subjects: 45
Study 17261985 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise only (Group 2)
Number of subjects: 45
Study 15520361 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS)
Number of subjects: 28
Study 15520361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 11405173 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined adjuvant 5‐fluorouracil‐based chemotherapy and radiotherapy
Number of subjects: 236
Study 9272360 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular vaccines (Chiron Biocine three-component and SmithKline Beecham three-component)
Number of subjects: 1275
Study 9272360 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-cell study vaccine (produced by Connaught Laboratories, Inc.)
Number of subjects: 1275
Study 7944455 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-lymph nodal injection of MMC-CH 40
Number of subjects: 95
Study 7944455 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 95
Study 3277804 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized terbutaline (10 mg)
Number of subjects: 69
Study 3277804 — intervention group
Group type: COMPARATOR
Intervention: Intravenous enprofylline (2 mg/kg)
Number of subjects: 69
Study 29131414 — intervention group
Group type: EXPERIMENTAL
Intervention: OHIP-5 score of 3 or higher on at least two of the five items
Number of subjects: 3500
Study 29194244 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation experience during postpartum hemorrhage scenario
Number of subjects: 7
Study 25678546 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity training (10 min warm-up followed by 4×4 min intervals at ∼90% of peak heart rate)
Number of subjects: 1567
Study 25678546 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity training (50 min of continuous work at ∼70% of peak heart rate)
Number of subjects: 1567
Study 25678546 — intervention group
Group type: COMPARATOR
Intervention: Control group following physical activity advice according to national recommendations
Number of subjects: 1567
Study 23117243 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoid (GC) bridging therapy response at 2 weeks
Number of subjects: 120
Study 23117243 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy arms and baseline DAS
Number of subjects: 120
Study 21402164 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg D-cycloserine (DCS)
Number of subjects: 60
Study 21402164 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg valproic acid (VPA)
Number of subjects: 60
Study 21402164 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 100 mg DCS and 400 mg VPA
Number of subjects: 60
Study 21402164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 18303228 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost
Number of subjects: 82
Study 18303228 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost
Number of subjects: 82
Study 21949042 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV)
Number of subjects: 55
Study 21949042 — intervention group
Group type: COMPARATOR
Intervention: Trivalent inactivated vaccine (TIV)
Number of subjects: 55
Study 15635596 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 0
Study 15635596 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with newer agents (e.g., taxanes)
Number of subjects: 0
Study 12377810 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic relaxation
Number of subjects: 20
Study 12377810 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger
Number of subjects: 20
Study 12377810 — intervention group
Group type: EXPERIMENTAL
Intervention: Happiness
Number of subjects: 20
Study 12377810 — intervention group
Group type: COMPARATOR
Intervention: Awake (control)
Number of subjects: 20
Study 10518858 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal Mouth and Gum Therapy
Number of subjects: 40
Study 10518858 — intervention group
Group type: COMPARATOR
Intervention: Control (distilled water and dye)
Number of subjects: 40
Study 8124953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 8124953 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐1ra 17 mg/hr
Number of subjects: 99
Study 8124953 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐1ra 67 mg/hr
Number of subjects: 99
Study 8124953 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐1ra 133 mg/hr
Number of subjects: 99
Study 8124953 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐1ra treatment in septic shock
Number of subjects: 99
Study 8124953 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐1ra treatment in Gram-negative infection
Number of subjects: 99
Study 8124953 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐1ra treatment in patients with IL‐6 > 100 pg/mL
Number of subjects: 99
Study 8124953 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐1ra treatment
Number of subjects: 99
Study 2536789 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of RIT 4237 attenuated rotavirus vaccine
Number of subjects: 391
Study 2536789 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of RIT 4237 attenuated rotavirus vaccine
Number of subjects: 391
Study 12824829 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment
Number of subjects: 121
Study 12824829 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 121
Study 31569256 — intervention group
Group type: EXPERIMENTAL
Intervention: REVISE ACL Classification using CT scan analysis
Number of subjects: 10
Study 31735538 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedD) and increased physical activity for 12 months
Number of subjects: 68
Study 31735538 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group (CG)
Number of subjects: 68
Study 31735538 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 68
Study 30180087 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamate injection (1 mol/L or 0.25 mol/L)
Number of subjects: 60
Study 30180087 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical stimulation (pressure applied to the masseter muscle with 4 different forces: 0.5, 1, 2, and 4 kg)
Number of subjects: 60
Study 30180087 — intervention group
Group type: EXPERIMENTAL
Intervention: Painful stimulus
Number of subjects: 60
Study 30180087 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity of stimulus
Number of subjects: 60
Study 30180087 — intervention group
Group type: EXPERIMENTAL
Intervention: RS centre-of-gravity location
Number of subjects: 60
Study 27116682 — intervention group
Group type: EXPERIMENTAL
Intervention: γ-tACS
Number of subjects: 10
Study 27116682 — intervention group
Group type: COMPARATOR
Intervention: tDCS
Number of subjects: 10
Study 27116682 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 10
Study 24507766 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy with a mean dose to the whole and inferior rectum
Number of subjects: 90
Study 24507766 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy with a median volume of rectum treated to ≥70 Gy (V70)
Number of subjects: 90
Study 24507766 — intervention group
Group type: EXPERIMENTAL
Intervention: Low (V25-V40), intermediate (V50-V60), and high (V70-V80) doses to the inferior rectum
Number of subjects: 90
Study 24507766 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest dose (V80) to the mid-rectum
Number of subjects: 90
Study 23139250 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum 25-hydroxyvitamin D concentrations
Number of subjects: 1101
Study 23139250 — intervention group
Group type: EXPERIMENTAL
Intervention: Quartile models of serum 25-hydroxyvitamin D concentrations
Number of subjects: 1101
Study 23139250 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D concentrations
Number of subjects: 1101
Study 20336077 — intervention group
Group type: EXPERIMENTAL
Intervention: Poractant alfa
Number of subjects: 50
Study 20336077 — intervention group
Group type: COMPARATOR
Intervention: Beractant
Number of subjects: 50
Study 18759650 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (n = 13)
Number of subjects: 22
Study 18759650 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 9)
Number of subjects: 22
Study 15925644 — intervention group
Group type: EXPERIMENTAL
Intervention: Trait adjectives
Number of subjects: 0
Study 15925644 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional and physiological adjectives
Number of subjects: 0
Study 12968980 — intervention group
Group type: COMPARATOR
Intervention: Loperamide
Number of subjects: 0
Study 12968980 — intervention group
Group type: COMPARATOR
Intervention: Tegaserod
Number of subjects: 0
Study 12968980 — intervention group
Group type: COMPARATOR
Intervention: Alosetron
Number of subjects: 0
Study 12968980 — intervention group
Group type: COMPARATOR
Intervention: Tricyclic antidepressants
Number of subjects: 0
Study 12968980 — intervention group
Group type: COMPARATOR
Intervention: Selective serotonin reuptake inhibitors
Number of subjects: 0
Study 12968980 — intervention group
Group type: COMPARATOR
Intervention: Laxatives
Number of subjects: 0
Study 12968980 — intervention group
Group type: COMPARATOR
Intervention: Anticholinergic and antispasmodic agents
Number of subjects: 0
Study 10579482 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mg/kg dextromethorphan
Number of subjects: 40
Study 10579482 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 mg/kg dextromethorphan
Number of subjects: 40
Study 10579482 — intervention group
Group type: COMPARATOR
Intervention: 0.05 mg/kg dextromethorphan
Number of subjects: 40
Study 10579482 — intervention group
Group type: COMPARATOR
Intervention: 0.15 mg/kg dextromethorphan
Number of subjects: 40
Study 10579482 — intervention group
Group type: COMPARATOR
Intervention: 0.3 mg/kg dextromethorphan
Number of subjects: 40
Study 10579482 — intervention group
Group type: COMPARATOR
Intervention: 30 mg dextromethorphan
Number of subjects: 40
Study 7574017 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (1.5‐2.0 mg/kg, intravenously) + nitrous oxide 60% in oxygen + propofol infusion (75‐160 micrograms.kg‐1.min‐1 IV)
Number of subjects: 146
Study 7574017 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (1.5‐2.0 mg/kg, intravenously) + nitrous oxide 60% in oxygen + sevoflurane (1%‐2% end‐tidal)
Number of subjects: 146